title: Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.
abstract: BACKGROUND
  Advanced and recurrent ovarian cancer results in extensive spread of tumor on the peritoneal surfaces of the abdomen and pelvis. We collectively review studies in the literature that report the efficacy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer peritoneal carcinomatosis.
  
  
  METHODS
  An electronic search of all relevant studies published in peer-reviewed journals before May 2009 was performed on three databases. The quality of each study was independently assessed and classified according to the time point of HIPEC use in various setting of ovarian cancer from the consensus statement of the Peritoneal Surface Oncology Group. Clinical efficacy was synthesized through a narrative review with full tabulation of the results of each included study.
  
  
  RESULTS
  Nineteen studies each of more than ten patients reporting treatment results of HIPEC of patients with both advanced and recurrent ovarian cancer were included and data were extracted. All studies were observational case series. The overall rate of severe perioperative morbidity ranged from 0 to 40% and mortality rate varied from 0 to 10%. The overall median survival following treatment with HIPEC ranged from 22 to 64 months with a median disease-free survival ranging from 10 to 57 months. In patients with optimal cytoreduction, a 5-year survival rate ranging from 12 to 66% could be achieved.
  
  
  CONCLUSIONS
  Despite the heterogeneity of the studies reviewed, current evidence suggest that complete CRS and HIPEC may be a feasible option with potential benefits that are comparable with the current standard of care. A randomized trial is required to establish the role of HIPEC in ovarian cancer.
authors.affiliation: Department of Surgery, St George Hospital, University of New South Wales, Kogarah, Sydney, NSW 2217, Australia. Terence.Chua@unsw.edu.au
authors.forename: Terence C
authors.initials: TC
authors.lastname: Chua
authors.forename: Greg
authors.initials: G
authors.lastname: Robertson
authors.forename: Winston
authors.initials: W
authors.lastname: Liauw
authors.forename: Rhonda
authors.initials: R
authors.lastname: Farrell
authors.forename: Tristan D
authors.initials: TD
authors.lastname: Yan
authors.forename: David L
authors.initials: DL
authors.lastname: Morris
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000453:epidemiology / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral; D007430:Intraoperative Care / Q000379:methods*; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010052:Ovariectomy / Q000379:methods*; D010534:Peritoneal Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000556:secondary / Q000628:therapy*; D011183:Postoperative Complications / Q000453:epidemiology / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references.citation: J Surg Oncol. 2008 Sep 15;98(4):283-90
references.pmid: 18726895
references.citation: Ann Oncol. 2007 Aug;18(8):1348-53
references.pmid: 17470449
references.citation: Int J Gynecol Cancer. 2004 Jan-Feb;14(1):35-41
references.pmid: 14764027
references.citation: World J Surg. 2004 Oct;28(10):1040-5
references.pmid: 15573262
references.citation: J Surg Oncol. 2006 Sep 15;94(4):316-24
references.pmid: 16917864
references.citation: J Anat. 1995 Jun;186 ( Pt 3):453-67
references.pmid: 7559120
references.citation: Gynecol Oncol. 2006 Dec;103(3):1070-6
references.pmid: 16875720
references.citation: Gynecol Oncol. 2007 Jul;106(1):193-200
references.pmid: 17466362
references.citation: Ann Oncol. 2003 Jul;14(7):1094-9
references.pmid: 12853352
references.citation: Eur J Surg Oncol. 2009 Nov;35(11):1186-91
references.pmid: 19356887
references.citation: Gynecol Oncol. 2009 Mar;112(3):439-40
references.pmid: 19245944
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1161-3
references.pmid: 11870155
references.citation: Cancer Treat Rev. 2001 Dec;27(6):365-74
references.pmid: 11908929
references.citation: Zentralbl Gynakol. 2003 Oct;125(10):424-9
references.pmid: 14628225
references.citation: J Obstet Gynaecol Res. 2006 Dec;32(6):580-7
references.pmid: 17100820
references.citation: Int J Hyperthermia. 2007 Aug;23(5):431-42
references.pmid: 17701534
references.citation: Ann Surg. 2009 Jun;249(6):900-7
references.pmid: 19474692
references.citation: J Clin Oncol. 2002 Mar 1;20(5):1248-59
references.pmid: 11870167
references.citation: Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:3-11
references.pmid: 15839952
references.citation: Gynecol Oncol. 2006 Jan;100(1):27-32
references.pmid: 16368440
references.citation: J Clin Oncol. 2006 Aug 20;24(24):4011-9
references.pmid: 16921055
references.citation: J Clin Oncol. 2007 Aug 20;25(24):3621-7
references.pmid: 17704411
references.citation: Cancer Metastasis Rev. 2003 Dec;22(4):465-72
references.pmid: 12884919
references.citation: Anticancer Res. 2003 May-Jun;23(3C):3019-27
references.pmid: 12926156
references.citation: J Surg Oncol. 2005 May 1;90(2):51-6; discussion 56-8
references.pmid: 15844187
references.citation: Cancer Res. 1980 Feb;40(2):256-60
references.pmid: 6766084
references.citation: World J Surg Oncol. 2004 Jun 28;2:21
references.pmid: 15222884
references.citation: Ann Surg Oncol. 2007 Feb;14(2):484-92
references.pmid: 17054002
references.citation: World J Surg. 2007 Sep;31(9):1813-1820
references.pmid: 17629740
references.citation: Ann Oncol. 2007 May;18(5):827-34
references.pmid: 17130182
references.citation: Cancer. 1996 Nov 15;78(10):2049-62
references.pmid: 8918397
references.citation: Ann Surg. 1995 Jan;221(1):29-42
references.pmid: 7826158
references.citation: Eur J Surg Oncol. 2006 Aug;32(6):671-5
references.pmid: 16621425
references.citation: Gynecol Oncol. 2009 Jul;114(1):137-9; author reply 139
references.pmid: 19368962
references.citation: Int J Gynecol Cancer. 2005 Mar-Apr;15(2):233-9
references.pmid: 15823105
references.citation: Cancer. 2007 Feb 15;109(4):685-91
references.pmid: 17219441
references.citation: Gynecol Oncol. 2009 Jun;113(3):335-40
references.pmid: 19345401
references.citation: World J Surg Oncol. 2009 Feb 09;7:14
references.pmid: 19203351
references.citation: Cancer Treat Res. 1996;82:359-74
references.pmid: 8849962
references.citation: Gynecol Oncol. 2007 Apr;105(1):90-6
references.pmid: 17173957
references.citation: Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:26-8
references.pmid: 18336395
references.citation: Gynecol Oncol. 2004 Aug;94(2):325-32
references.pmid: 15297169
references.citation: Cancer Treat Res. 1996;82:79-100
references.pmid: 8849945
references.citation: Cancer. 2008 Jul 15;113(2):315-25
references.pmid: 18473354
references.citation: J Natl Cancer Inst. 2009 Jun 3;101(11):775-7
references.pmid: 19470952
references.citation: J Clin Oncol. 2006 Oct 10;24(29):4699-707
references.pmid: 16966687
references.citation: J Surg Oncol. 2000 May;74(1):41-4
references.pmid: 10861608
references.citation: Cancer. 2000 Nov 15;89(10):2068-75
references.pmid: 11066047
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: N Engl J Med. 2006 Jan 5;354(1):34-43
references.pmid: 16394300